Prevention of Postoperative Nausea and Vomiting After Gynaecological day Surgery Under Remimazolam General Anesthesia

A Randomized Double-blind Controlled Study

Fuxia Yi; Hongyi Xiao; Teng Zhu; Yan Man; Fanceng Ji


BMC Anesthesiol. 2022;22(292) 

In This Article


One hundred ninety-two patients were included, six were excluded and six were rejected, and data from 180 patients in the PACU and 145 patients at 24 h postoperatively were obtained for statistical analysis (Figure 1).

Figure 1.

A total number of 192 patients were randomized into three groups (n = 64). For various reasons (Hypertension, Allergy, Diabetes or Declined to participate), 2 patients in DD the group, 4 patients in the DT group and 6 patients in the DC group did not receive trial medication. Thus 180 patients were analyzed: 62 patients in the DD group, 60 patients in the DT group, 58 patients in the DC group. For 35 patients lost to follow up after discharge, 145 patients were analyzed: 47 patients in the DD group, 51 patients in the DT group, 47 patients in the DC group

There were no significantly differences between the three groups in the basic data of patients such as age, weight, height, BMI, ASA grade, Apfel score, type of surgery and the dosage of remimazolam and alfentanil and duration of surgery (P > 0.05) (Table 1).

The incidence of PONV in the PACU was significantly lower in the DD(14.5%) and DT (26.7%)groups than in the DC(50%) group (P < 0.01) (Table 1), and the difference between the DD and DT groups was not significantly (P > 0.05) (Table 2). The incidence of PONV in 24 h after surgery was no significantly difference between the three groups (DD:DT:DC = 44.5%:45.1%:63.8%,P > 0.05) (Table 2).